Tempus AI, Inc. (TEM)
Tempus AI uses massive datasets and artificial intelligence to help doctors personalise cancer treatments and speed up medical research.
Is Tempus AI, Inc. a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: Strong revenue growth of over 36%. Worth weighing: Currently losing money on a net basis.
Is this normal for this company?
Each figure against the range this same company has produced recently. Neither end of a range is the good end.
Profit as a share of sales, from the company's own quarterly statements. The range covers the 5 quarters we hold, and the figure shown is its most recent one.
How these ranges are built
Every number here is the company's own reported figure, not a comparison with other companies. The ranges come from this company's own results and its share price. Where it reports in a different currency from the one its shares trade in, the price-to-earnings range is left out rather than mixing the two.
What does Tempus AI, Inc. do?
Tempus AI acts like a high-tech librarian for healthcare, gathering vast amounts of clinical and genetic data to help doctors choose the best treatments for individual patients. Revenue comes from selling pharmaceutical companies and hospitals access to this data and their analytical tools. Whether they can convert rapid growth into actual profit is the real question, since they currently spend more than they earn.
On our factor screen it looks strongest on growth and value, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 22% over the year
- !Carries a lot of debt - roughly 3.2x its equity
- Growth screens high
- Quality screens low
- Income screens low
Does Tempus AI, Inc. pay a dividend?
No - Tempus AI, Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
Does Tempus AI, Inc. have more cash or more debt?
It holds about $815.99M in cash against about $1.44B of debt - so it has net debt of about $628.18M. Debt is not automatically a problem - it funds growth - but it has to be serviced and repaid, which matters more when profits wobble.
From the latest reported balance sheet. Cash and debt levels change, and some borrowing is normal - this is context, not a judgment.
What do Tempus AI, Inc.'s numbers mean?
How has it performed?
Growth of £1,000, the worst fall, and year by year
Over about 2 years to 2026-09-11. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has Tempus AI, Inc. actually fallen?
Over the last 2 years of daily prices, Tempus AI, Inc. fell as much as −60% from a high to a later low. Falls like this are normal when you own a share.
Past falls are not a forecast - it can fall further, or recover.
How has it done year by year?
Calendar-year total return - the share price with dividends reinvested - from adjusted closing prices. The current year is only part-complete. Past returns are not a guide to the future.
A closer look at the numbers
Ownership, earnings history, where the money goes, and the outlook range
Does the share price tell you if it's cheap or expensive?
Who owns Tempus AI, Inc.?
About 54% of Tempus AI, Inc., or about 54 in every 100 shares, is held by big institutions such as pension and index funds, and company insiders hold about 37%. The rest, roughly 9%, is held by the public and smaller investors.
What this does and doesn't tell you
This is a recent snapshot of the share register, and it moves. We don't read anything into who owns what - a high institutional share is common for any large listed company and is not a signal about it.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
How much money does Tempus AI, Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
When does Tempus AI, Inc. report earnings, and how did recent quarters go?
Tempus AI, Inc. is next scheduled to report on about 2026-11-03 - dates can move, and we don't predict results; this just tells you when to look.
‘Beat’ and ‘missed’ are against what analysts expected, not whether the business is doing well.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-07-30 | $-0.15 | $-0.04 | Beat +74% |
| 2026-05-05 | $-0.20 | $-0.13 | Beat +35% |
| 2026-02-24 | $-0.05 | $-0.04 | Beat +22% |
| 2025-11-04 | $-0.18 | $-0.11 | Beat +37% |
| 2025-08-08 | $-0.25 | $-0.22 | Beat +13% |
| 2025-05-06 | $-0.27 | $-0.24 | Beat +10% |
Across the last 6 quarters here, Tempus AI, Inc. came in ahead of what analysts expected 6 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Where these figures come from
Each quarter a company reports its results against a consensus of analyst forecasts. The figures here are reported versus expected earnings per share from published results; the expectation is that analyst consensus, not our view. Report dates are estimates and can move.
What are the scenarios for Tempus AI, Inc.?
An illustrative range for the year ahead — not a prediction or a price target.
What are the pros, cons and common questions?
The case each way, and the questions people ask
Tempus becomes an essential standard for data-driven medicine globally.
Failure to differentiate from larger tech rivals or regulatory hurdles.
What are the pros and cons of Tempus AI, Inc.?
A balance check, not a score or verdict.
- Strong revenue growth: How fast the company's sales grew versus a year ago. of over 36%
- High gross margins suggest a scalable product
- Operates in the high-potential intersection of AI and healthcare
- Currently losing money on a net basis
- Very high price-to-book: The share price versus the company's net assets per share (its book value). Under 1 can look cheap, though it varies a lot by industry. ratio suggests a premium valuation
- No dividend payments for investors
- High volatility makes it a bumpy ride for investors
- Heavy reliance on the evolving regulatory landscape for AI in medicine
- Risk of burning through cash reserves before reaching profitability
The write-up's own warning lights — if these start happening, the case above changes.
- A sustained shift to positive net income
- A significant drop in revenue growth rates
- Major changes in data privacy laws that restrict their business model
Common questions about Tempus AI, Inc.
Does Tempus AI, Inc. pay a dividend?
No - Tempus AI, Inc. does not currently pay a dividend, so the return would rest on the share price. Many growing companies reinvest profits instead of paying them out.
When does Tempus AI, Inc. report earnings next?
Tempus AI, Inc. is next scheduled to report results on about 2026-11-03. Report dates are estimates and can move; this is a diary note for when to look, not a forecast of the outcome.
More in Healthcare
CRISPR Therapeutics AG
Intuitive Surgical, Inc.
BioNTech SE
Hims & Hers Health, Inc.
Intellia Therapeutics, Inc.
Novavax, Inc.
Smith & Nephew
Bristol-Myers Squibb CompanyBuilt from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.